TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06630403

Intervention type: OTHER
Intervention: Demographic Data
Description: Demographic data (age, height, weight, BMI) will be collected verbally through an assessment form.

Intervention type: OTHER
Intervention: Demographic Data
Description: Demographic data (age, height, weight, BMI) will be collected verbally through an assessment form.

Intervention type: OTHER
Intervention: Disease History
Description: The number of exacerbations in the last 1 year, hospitalization and medications used will be questioned.

Intervention type: OTHER
Intervention: Pulmonary Function Test
Description: Pulmonary Function Test will be performed with a spirometer.

Intervention type: OTHER
Intervention: Pulmonary Function Test
Description: Pulmonary Function Test will be performed with a spirometer.

Intervention type: OTHER
Intervention: Reaction Time
Description: Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test.

Intervention type: OTHER
Intervention: Reaction Time
Description: Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test.

Intervention type: OTHER
Intervention: Functional Capacity
Description: Functional capacity will be evaluated with 6 minute walk test

Intervention type: OTHER
Intervention: Functional Capacity
Description: Functional capacity will be evaluated with 6 minute walk test

Intervention type: OTHER
Intervention: Dyspnea Perception
Description: Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea

Intervention type: OTHER
Intervention: Dyspnea Perception
Description: Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea

Intervention type: OTHER
Intervention: Quality of Life
Description: Quality of life will be assessed with the Quality of Life Scale for Children\&#34;

Intervention type: OTHER
Intervention: Quality of Life
Description: Quality of life will be assessed with the Quality of Life Scale for Children\&#34;

Intervention type: OTHER
Intervention: Fear of movement
Description: Fear of movement will be evaluated with Tampa Kinesiophobia Scale

Intervention type: OTHER
Intervention: Fear of movement
Description: Fear of movement will be evaluated with Tampa Kinesiophobia Scale

Intervention type: OTHER
Intervention: Ability of Motor Imagery
Description: Motor Imagery ability will be assessed by Movement Imagery Questionnaire-3 and Vividness of Movement Imagery

Intervention type: OTHER
Intervention: Ability of Motor Imagery
Description: Motor Imagery ability will be assessed by Movement Imagery Questionnaire-3 and Vividness of Movement Imagery

Intervention type: OTHER
Intervention: Cognitive Functions
Description: Cognitive functions will be assessed with Trail Making Test and Stroop Test

Intervention type: OTHER
Intervention: Cognitive Functions
Description: Cognitive functions will be assessed with Trail Making Test and Stroop Test
Study: NCT06172595

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FET PET
Description: There is only one study visit during which study subjects will undergo a 18F-FET PET/CT in SGH. Following that, they will be followed up as per their routine clinical care. Data collection timepoints will be at 30 days, 4 months, 8 months and 1 year.
Study: NCT04966156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaRE-4-alloBMT plus usual care group
Description: CaRE-4-alloBMT uses emerging eHealth technologies to reduce barriers to accessing and providing cancer rehabilitation which includes: 1) Individualized progressive exercise prescriptions that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials; 2) Individualized nutrition plans and stepped stratified care such as education, counselling, intervention based on nutritional status and delivered by registered dietitians; 3) On-line e-modules provide interactive education to promote self-management skills for stress management, nutrition, managing common symptoms, etc.; 4) Remote monitoring using FitbitTM devices to monitor patients physical activity, caloric intake, and sleep for duration of the program. CRS and alloBMT clinicians will have access to real-time Fitbit data through our clinical dashboard; 5) Remote clinical support: check-ins and health coaching sessions with a member of the CRS team (phone or MS Teams video).
Study: NCT05826444

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography with afterload change

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography with afterload change

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Stress-MRI
Study: NCT04265053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal Product
Description: In Aim 3, males receive this for 7-9 days of the ganirelix treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal Product
Description: In Aim 3, males receive this for 7-9 days of the ganirelix treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Topical
Description: In Aim 3, females receive this for 7-9 days of the ganirelix treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Topical
Description: In Aim 3, females receive this for 7-9 days of the ganirelix treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid
Description: Subjects will also be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Subjects will also be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid
Description: Subjects will also be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Subjects will also be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid
Description: Subjects will also be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Subjects will also be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacid
Description: Subjects will also be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Subjects will also be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.
Study: NCT05444517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block
Description: Ultrasound-guided brachial plexus block injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml in the Interscalene groove.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular - Anterior Supraescapular Nerve Blocks
Description: Ultrasound-guided combined infraclavicular-anterior suprascapular block of the brachial plexus, injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an ultrasound-guided injection of 3 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml under the omohyoid muscle. If the anterior suprascapular nerve could not be identified after five minutes of insonation time, an upper trunk block will be carried out with the same amount of local anesthetic.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml).
Study: NCT05826444

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Stress-MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetocardiography
Description: Magnetocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetocardiography
Description: Magnetocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Histology
Description: Histological analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Histology
Description: Histological analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetics
Description: miRNA sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetics
Description: miRNA sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: calcium signaling
Description: cardiomyocyte calcium signaling

Intervention type: DIAGNOSTIC_TEST
Intervention: calcium signaling
Description: cardiomyocyte calcium signaling

Intervention type: DIAGNOSTIC_TEST
Intervention: IMR
Description: Index of microvascular resistance measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: IMR
Description: Index of microvascular resistance measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Angio-IMR
Description: Angiography derived post-processing index if microvascular resistance

Intervention type: DIAGNOSTIC_TEST
Intervention: Angio-IMR
Description: Angiography derived post-processing index if microvascular resistance
Study: NCT04542148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sliding Scale Insulin
Description: After antenatal corticosteroid administration, women will continue to receive long- and short-acting subcutaneous insulin injections as prescribed at home. In addition, they will receive supplemental short-acting insulin using a sliding scale based on postprandial glucose values. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Up-Titration of Home Insulin
Description: After antenatal corticosteroid administration, women will receive long- and short-acting subcutaneous insulin injections at increased dosages compared to that prescribed at home. Insulin will be increased by 30% on the day that they receive their 1st dose of antenatal corticosteroids (day 1), 50% on day 2, 50% on day 3, 30% on day 4, and 15% increase on day 5. On day 6 they will return to their home insulin regimen. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Insulin Infusion
Description: After antenatal corticosteroid administration, women will discontinue their home insulin regimen and be placed on a continuous insulin infusion with insulin boluses and titration of infusion rate per institutional L\&D protocol. Capillary blood glucose values will be measured with fingersticks every hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Professional Continuous Glucose Monitor
Description: Masked Dexcom G6 Pro devices will be worn for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Professional Continuous Glucose Monitor
Description: Masked Dexcom G6 Pro devices will be worn for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Professional Continuous Glucose Monitor
Description: Masked Dexcom G6 Pro devices will be worn for 10 days.
Study: NCT03826693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen
Description: OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
Study: NCT04656002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours
Study: NCT05331612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended intervention condition
Description: Participants receive the online protocol treatment and face-to-face sessions during 13 weeks.
Study: NCT05173493

Intervention type: DRUG
Intervention: Amoxicillin,Furazolidone
Description: Amoxicillin-Furazolidone-containing quadruple group

Intervention type: DRUG
Intervention: Amoxicillin,Levofloxacin
Description: Amoxicillin-Levofloxacin-containing quadruple group

Intervention type: DRUG
Intervention: Tetracycline,Furazolidone
Description: Tetracycline-Furazolidone-containing quadruple group
Study: NCT04861740

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Intervention
Description: Autism screening intervention only.
Study: NCT06025552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU7710
Description: In each dose level, 6 subjects will be assigned to TU7710. Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, 800mcg/kg and the last dose will be decided after assessing cohort 1\~4 PK, PD, safety, and exploratory efficacy data.
Study: NCT05849207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
Study: NCT06098573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Alert
Description: Participants assigned to the 'High Alert' condition will complete four interactive modules using their smartphones. These modules are hosted online via the Computerized Intervention Authoring Software, version 3.0 (https://www.cias.app \[CIAS\]). CIAS is a non- commercial, easily modifiable, web-based intervention platform used widely in the digital substance use literature. No identifiable information is requested or stored in CIAS. This program is only intended to deliver the content interactively. None of the questions asked in CIAS will be treated as research data. We will only report on the proportion of questions answered by participants (as a measure of adherence). Individual responses to questions will not be analyzed nor reported on. The purpose of the questions is for participants to engage with the content interactively
Study: NCT06631859

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cosmetic products containing 0% Assam tea
Description: Cosmetic products containing 0% Assam tea

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic products containing 2.5% Assam tea
Description: Cosmetic products containing 2.5% Assam tea
Study: NCT04515394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
Study: NCT04760301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local tranexamic acid injection
Description: local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: local normal saline injection to cervix
Description: local normal saline injection to the cervix- 20 ml saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV 1 g tranexamic acid
Description: IV 1 g tranexamic acid diluted in 100 ml saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV 1 g normal saline
Description: IV 100 ml normal saline
Study: NCT04515394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants received weekly intravenous infusions of Cetuximab at a dose of 250 milligrams per square meter (mg/m\^2) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
Study: NCT06142240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise programe
Description: The components of the exercise programe will be: muscle strength training and continuous-variable aerobic training or HIIT with loads between 70-90% of maximum heart rate. The aerobic training will last about 30 minutes and will then be completed with muscle training of the upper and lower limbs with loads determined according to the perception of effort (loads around 50-70%). The sessions will be monitored with pulse oximetry (heart rate and oxygen saturation), perception of fatigue and sensation of suffocation (Borg scale). The intensity of each component of the programme will be individualised according to the conditions of each subject.~Adherence to the programme will be recorded as successful when participation in the sessions is greater than 80% of the total number of sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise programe
Description: The components of the exercise programe will be: muscle strength training and continuous-variable aerobic training or HIIT with loads between 70-90% of maximum heart rate. The aerobic training will last about 30 minutes and will then be completed with muscle training of the upper and lower limbs with loads determined according to the perception of effort (loads around 50-70%). The sessions will be monitored with pulse oximetry (heart rate and oxygen saturation), perception of fatigue and sensation of suffocation (Borg scale). The intensity of each component of the programme will be individualised according to the conditions of each subject.~Adherence to the programme will be recorded as successful when participation in the sessions is greater than 80% of the total number of sessions.
Study: NCT04809402

Intervention type: OTHER
Group type: OTHER
Intervention: remote monitoring after cataract surgery
Description: remote monitoring after cataract surgery
Study: NCT06558591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation intervention
Description: Inclusion will take place within the framework of routine care for individuals with chronic diseases in rehabilitation services, hospitals, institutions, etc. The study will be offered to patients with chronic illnesses who are being cared for by their therapists. Data collection will be conducted in two sessions. The period between the two sessions will be determined based on the patient's availability, not exceeding a period of 12 weeks:~1. 1st session at 0 week : Conducting activities and initial evaluation at their usual care center. Therapists will perform the various planned tests and evaluations.~2. 2nd session at 12 weeks : This session will take place under the same conditions as the first one and without any potential health risks to the participants.~3. A final evaluation will be carried out at the 18-week follow-up. A telephone call will be made between sessions to check in and assist participants in case of any issues during the study.
Study: NCT06240039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluating the acute effect of an amino acid infusion with and without a concomitant infusion of the somatostatin analogue octreotide to eliminate endogenous production of glucagon
Description: The experimental days consist of four study days:~1. Assessment of liver fat and visceral fat by magnetic resonance imaging (MRI; 6-point Dixon) (study day A)~2. Somatostatin infusion (4 hours) plus amino acid infusion (45 minutes) (study day B)~3. Saline infusion (4 hours) plus amino acid infusion (45 minutes) (study day C)~4. Somatostatin infusion (4 hours) plus saline infusion (45 minutes) (study day D)~The subjects will participate in the experimental days (study day B to D) in randomized order on three different days. For study day B to D, at timepoint t = -75, subjects will receive either; a 240-minute intravenous infusion of a somatostatin analogue (at 200 ng/kg/min (infusion rate will not exceed 1000 µg/hour) or saline. After 75 minutes (timepoint t = 0), the subjects will receive a 45-minute intravenous infusion of amino acids or saline at 3.885 ml/kg/hour.~In total, blood will be sampled 11 times over a period of 6 hours and 15 minutes.
Study: NCT05560828

Intervention type: OTHER
Intervention: Zio XT service
Description: There will be no intervention. Standard of care at participating NHS organizations will not be affected.
Study: NCT05390476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 500mg orally three times a day (continuously)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 500mg orally three times a day (continuously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: 20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
Study: NCT05100966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FitJoints Multi-modal Intervention
Description: Exercise: The study physiotherapist will prescribe an exercise program tailored to the participant's individual ability and preference with functional movements to mimic activities of daily living.~Nutritional consultation and protein supplement: The site research assistant will coach participants to improve their nutrition, determine their daily protein target, and provide educational tools on how to achieve their target. Protein supplements will be provided to participants.~Vitamin D: Participants will be provided with vitamin D3 (1000 IU) tablets to reduce the risk of falls and to preserve muscle strength and functional ability. They will be instructed to take one tablet daily for the duration of the intervention period.~Medication optimization: The study pharmacist will conduct a medication review and provide, if required, recommendations for medication optimization.
Study: NCT06025552

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
Study: NCT05795829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument
Description: Disposable intravascular ultrasound ablation catheters (used with an ultrasound ablation instrument) can use ultrasound energy to block sympathetic activity in the renal arteries.
Study: NCT05992519

Intervention type: DIAGNOSTIC_TEST
Intervention: ¸FeNO
Description: FeNO measured with a NIOX VERO device after the methacholine challenge
Study: NCT04749979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agonist (decapeptyl )
Description: giving agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG ( eg. Choriomon )
Description: giving HCG
Study: NCT04615689

Intervention type: OTHER
Intervention: The collection of feces
Description: When the infants will be diagnosed with urinary tract infection, feces will be collected. Feces will be collected from healthy infants with informed consent.

Intervention type: OTHER
Intervention: The collection of feces
Description: When the infants will be diagnosed with urinary tract infection, feces will be collected. Feces will be collected from healthy infants with informed consent.